Precision Pathways: Targeted Therapies, Mutation-Driven Treatment Strategies
Panelists discuss how the introduction of oral targeted therapies has transformed the patient experience by offering actionable treatment options for identifiable mutations, influencing prognosis and treatment discussions, and altering the nature of initial patient conversations, while Dr Isaacs highlights key efficacy and safety data from the INAVO120 trial and the implications of inavolisib’s PI3Kα-specific mechanism, and Dr Kaklamani addresses the evolving rationale for targeting truncal mutations earlier in treatment, emphasizing the role of combination therapies in first-line settings and trials such as ELEVATE/ELECTRA and CAPItello-292.
Video content above is prompted by the following:
- Dr Kaklamani asks Ms Diaz: How has the introduction of these oral targeted therapies changed the patient experience? What does it mean for patients to know they have actionable mutations that can be targeted?
- How do these targeted options influence your discussions about prognosis and treatment planning with patients? Has it changed the nature of those initial conversations?
- Dr Kaklamani asks Dr Isaacs: Please highlight the key efficacy and safety data from the INAVO120 trial that led to approval.
- What implications does inavolisib’s PI3Kα-specific mechanism of action have for its safety and efficacy compared to less specific agents such as capivasertib?
- Dr Kaklamani addresses: This brings up an important point about the evolving landscape and emerging rationale for targeting truncal mutations earlier in treatment. As precision medicine informs earlier treatment lines, please expand on the rationale for targeted therapy combinations in earlier lines of treatment. Additionally, could you highlight the ELEVATE/ELECTRA and CAPItello-292 trials and this shift toward combination strategies in the first-line and earlier treatment settings?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
